How decentralisation can fill the gaps in Alzheimer’s research
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and Eisai…
Central Nervous System
-
-
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit
AC Immune’s stock price has jumped by more than 20% after all patients in a trial of its Parkinson’s disease…
-
Intra-Cellular bolsters Caplyta data with another Phase III win
Having raised the full-year sales guidance for Caplyta (lumateperone) a week ago, Intra-Cellular Therapeutics has reported positive topline data from…
-
Roche’s Alzheimer’s test shows high negative predictive value
Roche has presented new late-breaking data from a prospective trial showing that its Elecsys amyloid plasma panel can rule out…
-
ARIA-E risk of Lilly’s Kisunla in Alzheimer’s reduced with modified dosing
A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related imaging abnormalities with…
-
Onward raises $54m to continue neuromodulation trials
Onward Medical has raised $54m (€50m) via a bookbuild offering, with proceeds going towards ongoing clinical studies and an expected…
-
Amylyx’s AMX0035 shows promise in Phase II Wolfram syndrome trial
Amylyx Pharmaceuticals has announced positive topline results from the Phase II HELIOS clinical trial, indicating sustained improvements with AMX0035 in…
-
Genentech’s Evrysdi helped babies with SMA reach rare milestones in Phase II trial
Roche’s spinal muscular atrophy (SMA) drug Evrysdi (risdiplam) has helped pre-symptomatic babies reach rare milestones after two years of treatment…
-
Cassava Sciences: Phase III trials storm ahead amid controversy
Cassava Sciences is moving forward with Phase III trials after paying $40m to settle an SEC case alleging misleading data…
-
Scholar Rock stocks skyrocket after SMA drug scores at Phase III
Scholar Rock’s stock has soared off the back of positive Phase III results from its spinal muscular atrophy (SMA) candidate.…
